Brought to you by 
Takeda takes ex-US rights to TiGenix's stem cell-based fistula therapy; Takeda later buys TiGenix
24 May 2021
Executive Summary
TiGenix NV granted Takeda Pharmaceutical Co. Ltd. exclusive rights to develop and commercialize Cx601 in all territories outside of the US for perianal fistulas in patients with Crohn's disease.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Takeda takes ex-US rights to TiGenix's stem cell-based fistula therapy; Takeda later buys TiGenix
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice